<DOC>
	<DOCNO>NCT01767766</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness TGR-1202 patient advance hematologic malignancy .</brief_summary>
	<brief_title>Evaluate Safety Efficacy TGR 1202 Patients With Relapsed Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>Refractory relapse least 1 prior treatment regimen ; Eastern Cooperative Oncology Group ( ECOG ) score 0 2 ; At least 18 year age . Any major surgery , chemotherapy immunotherapy within last 21 day ( limited palliative radiation allow â‰¥ 2 week ) ; Autologous hematologic stem cell transplant within 3 month study entry Allogeneic hematologic stem cell transplant within 12 month ; Known hepatitis B virus , hepatitis C virus HIV infection ; Previous therapy GS1101 ( CAL101 ) , IPI145 drug specifically inhibit PI3K mTOR pathway ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>